News articles about Regeneron Pharmaceuticals (NASDAQ:REGN) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.5434596069116 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

Regeneron Pharmaceuticals (NASDAQ REGN) traded up 0.94% during trading on Wednesday, hitting $474.09. The stock had a trading volume of 979,959 shares. The company has a 50 day moving average of $499.39 and a 200-day moving average of $422.69. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $543.55. The company has a market cap of $50.05 billion, a P/E ratio of 57.39 and a beta of 1.66.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 EPS for the quarter, beating analysts’ consensus estimates of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The firm had revenue of $1.47 billion for the quarter, compared to the consensus estimate of $1.36 billion. During the same quarter in the previous year, the company posted $2.82 earnings per share. The business’s quarterly revenue was up 21.2% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals will post $14.84 EPS for the current year.

A number of brokerages have recently weighed in on REGN. UBS AG set a $489.00 price target on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $472.00 price target (up previously from $469.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. J P Morgan Chase & Co restated a “neutral” rating and issued a $455.00 price target (up previously from $427.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Jefferies Group LLC restated a “hold” rating and issued a $471.00 price target (up previously from $418.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday. Finally, Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $540.00 price target for the company in a research report on Wednesday. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $489.35.

COPYRIGHT VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/regeneron-pharmaceuticals-regn-receiving-somewhat-positive-news-coverage-analysis-shows/1466732.html.

In other news, Director Michael S. Brown sold 3,000 shares of the company’s stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the sale, the director now owns 3,000 shares in the company, valued at approximately $1,350,000. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total value of $4,423,360.30. Following the sale, the executive vice president now owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. Insiders sold 59,922 shares of company stock worth $28,733,105 in the last 90 days. Corporate insiders own 10.40% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.